Both DX-2930 and KALBITOR were identified using Dyax’s proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company’s CYRAMZA® (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.[/td_text_with_title]
Marshall Wace LLP have tried several times over the last years to short Genmab and have failed miserably. The 4th of december 2015 they announced that they finally have reduced their short in the company – after stubbornly have been entrenched in their position amidst an increase in share value of almost 50% in just 3 […]
Vi står overfor et nyt medicin eventyr i Danmark, på linie med Lundbecks Cipramil og Novo Nordisks Insulin præparater. Det lyder stort og det er det også, ikke mindst fordi Genmabs succes sker på det mest profitable segment indenfor medicinalprodukter, nemlig kræftbehandling. Genmab står således foran en veritabel forandring som virksomhed, hvor man – godt […]
Vi har fået en del danske kunder og jeg vil af og til bidrage på dansk med mit syn på mine stockpicks og markedet generelt. Vi fik præcis det rebound som vi spekulerede i for et par uger siden. Vi har i denne uge taget en position i en dansk bank, som handles under indre...
In this and the coming quarters Genmab is focusing on its late stage assets as they progress toward an approval for Daratumumab and expansion of the label for Arzerra. The revenue and cost side of the company is as expected, there are no crazy things going around in the balancesheet. But there were some eyeopening information from...
Company Announcement sBLA submitted to US FDA for ofatumumab as maintenance therapy in relapsed CLL by Novartis Submission based on data from interim results of Phase III PROLONG study Copenhagen, Denmark; July 22, 2015 — Genmab A/S (OMX: GEN) announced today that a supplemental Biologics License Application (sBLA) has been submitted to the U.S. Food and […]
Company Announcement Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc. Completion of submission triggers USD 15 million milestone payment to Genmab Copenhagen, Denmark; July 9, 2015 — Genmab A/S (OMX: GEN) announced its licensing partner Janssen Biotech, Inc. has completed the rolling submission of the Biologics License […]
This is a discussion of practioners of the advantages of known regiments in CLL. The basic conclusion is that Rituxiamab is the prevailing standard, with obinutuzumab as a potential newcomer with a diffenriated method of action. Ofatumumab is given more of a chance in a refrac setting.
Janssen has submitted a new Phase 4, early access treatment trial on Clinicaltrials. org the 15th June 2015. The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available for subjects with multiple myeloma who have received at least 3 prior lines of […]
Genmab held a presentation at Goldman Sachs 9th june 2015 following ASCO and recent BLA filing for Daratumumab. It was a 34 minute long Q&A session where we got some more insights in details in manufacturing and how Genmab sees the future for Daratumumab. The US plays a big role in any biotech and pharma […]
Gilead announces submission of a supplemental New Drug Application to use Zydelig® in combination with ofatumumab in previously treated patients with CLL Submission based on data presented at American Society of Clinical Oncology Meeting 2015 Copenhagen, Denmark; June 1, 2015 — Genmab A/S (OMX: GEN) announced today that Gilead has published that it has submitted […]
Genmab kom tirsdag d. 3. februar efter lukketid med data på et vigtigt studie for Daratumumab. Længe ventet kan man måske ikke kalde det, fordi udviklingen er i kræftmedicinsammenhæng gået meget hurtigt, men i forhold til kursudviklingen har det været ventet med længsel. Igennem en periode på 2 år er interessen for Daratumumab i Multiple […]
Efter Genmab´s fantastiske kursudvikling de sidste 2-3 år, hvor aktien er steget omkring 18 gange fra bunden, så spørger mange private investorer sikkert sig selv, hvordan – hvis overhovedet – man kan finde den næste Genmab case. En advarsel er på sin plads her, for grundlæggende er den slags stockpicking ikke vejen frem til en sund formue. […]